Intravitreal Beovu (Brolucizumab-dbl) Billing

National Government Services has seen multiple variations of billing from providers for Intravitreal Beovu. This job aid provides clarification and proper billing for this drug.

For Medicare billing purposes in Jurisdiction 6 and Jurisdiction K, the correct billing is HCPCS J3590. In addition to the HCPCS code, you would need to bill the appropriate dose of 6 mg. if it is being used for one eye or 12 mg. if both eyes are injected.

Billing J3590 RT and J3590 LT would also be acceptable for billing purposes of both eyes, each with six mg. Note: This information is for billing 2019 dates of service.

For 2020 dates of service there is a HCPCS code to use for billing, J0179. Information for billing this service in 2020 may be found is policy article A52451 Billing and Coding: Ranibizumab, Aflibercept and Brolucizumab-dbll and Faricimab-svoa. Please make sure to review the policy article for all coverage criteria.

Reviewed 3/26/2024